Anthracycline-based consolidation may determine outcome of post-consolidation immunotherapy in AML
Artikel i vetenskaplig tidskrift, 2019

Consolidation chemotherapy in acute myeloid leukemia (AML) aims at eradicating residual leukemic cells and mostly comprises high-dose cytarabine with or without the addition of anthracyclines, including daunorubicin. Immunogenic cell death (ICD) may contribute to the efficacy of anthracyclines in solid cancer, but the impact of ICD in AML is only partly explored. We assessed aspects of ICD, as reflected by calreticulin expression, in primary human AML blasts and observed induction of surface calreticulin upon exposure to daunorubicin but not to cytarabine. We next assessed immune phenotypes in AML patients in complete remission (CR), following consolidation chemotherapy with or without anthracyclines. These patients subsequently received immunotherapy with histamine dihydrochloride (HDC) and IL-2. Patients who had received anthracyclines for consolidation showed enhanced frequencies of CD8(+) T-EM cells in blood along with improved survival. We propose that the choice of consolidation therapy prior to AML immunotherapy may determine clinical outcome.

Acute myeloid leukemia

consolidation chemotherapy



cytotoxic T cells



Johan Aurelius

Göteborgs universitet

Lars Mollgard

Göteborgs universitet

Roberta Kiffin

Göteborgs universitet

Frida Ewald Sander

Göteborgs universitet

Staffan Nilsson

Chalmers, Matematiska vetenskaper, Tillämpad matematik och statistik

Göteborgs universitet

Fredrik Bergh Thoren

Göteborgs universitet

Kristoffer Hellstrand

Göteborgs universitet

Anna Martner

Göteborgs universitet

Leukemia and Lymphoma

1042-8194 (ISSN) 1029-2403 (eISSN)

Vol. 60 11 2771-2778


Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi


Cancer och onkologi





Mer information

Senast uppdaterat